Table 4.
TRK inhibitors clinical trials in NTRK fusion-positive solid tumors, including non-small cell lung cancer (NSCLC).
| Study Name | Phase | Inhibitors | Population with NTRK-Fusion Positive Solid Tumors | Enrollment (n) |
|---|---|---|---|---|
| NAVIGATE (NCT02576431) | II | Larotrectinib | Adults and children | 320 patients |
| STARTRK-2 (NCT02568267) | II | Entrectinib | NTRK-, ROS1- and ALK-fusion positive | 300 patients |
| NCT01639508 | I | Cabozantinib | NTRK fusion, or MET or AXL overexpression, amplification, or mutation | 68 patients |
| NCT03215511 | I/II | Selitrectinib | Adult and pediatric | 93 patients |
| TRIDENT-1 (NCT03093116) | I/II | Repotrectinib | NTRK-, ROS1- and ALK-fusion positive | 450 patients |
| NCT02675491 | I | DS-6051b | NTRK- or ROS1-fusion positive s | 15 patients |
| NCT01804530 | I | PLX7486 | NTRK-fusion positive | 59 patients-discontinued |
| NCT02920996 | II | Merestinib | NTRK-fusion positive or MET-mutation NSCLC | 25 patients |
| NCT03556228 | I | VMD-928 | NTRK1 alterations, including fusions, positive | 54 patients |
| NCT02219711 | I | Sitravatinib | NTRK-fusion positive NSCLC | 260 patients |